» Articles » PMID: 20958088

Cross-reactivity Virtual Profiling of the Human Kinome by X-react(KIN): a Chemical Systems Biology Approach

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2010 Oct 21
PMID 20958088
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Many drug candidates fail in clinical development due to their insufficient selectivity that may cause undesired side effects. Therefore, modern drug discovery is routinely supported by computational techniques, which can identify alternate molecular targets with a significant potential for cross-reactivity. In particular, the development of highly selective kinase inhibitors is complicated by the strong conservation of the ATP-binding site across the kinase family. In this paper, we describe X-React(KIN), a new machine learning approach that extends the modeling and virtual screening of individual protein kinases to a system level in order to construct a cross-reactivity virtual profile for the human kinome. To maximize the coverage of the kinome, X-React(KIN) relies solely on the predicted target structures and employs state-of-the-art modeling techniques. Benchmark tests carried out against available selectivity data from high-throughput kinase profiling experiments demonstrate that, for almost 70% of the inhibitors, their alternate molecular targets can be effectively identified in the human kinome with a high (>0.5) sensitivity at the expense of a relatively low false positive rate (<0.5). Furthermore, in a case study, we demonstrate how X-React(KIN) can support the development of selective inhibitors by optimizing the selection of kinase targets for small-scale counter-screen experiments. The constructed cross-reactivity profiles for the human kinome are freely available to the academic community at http://cssb.biology.gatech.edu/kinomelhm/ .

Citing Articles

Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors.

Singha M, Pu L, Stanfield B, Uche I, Rider P, Kousoulas K BMC Cancer. 2022; 22(1):1211.

PMID: 36434556 PMC: 9694576. DOI: 10.1186/s12885-022-10293-0.


Local Alignment of Ligand Binding Sites in Proteins for Polypharmacology and Drug Repositioning.

Brylinski M Methods Mol Biol. 2017; 1611:109-122.

PMID: 28451975 PMC: 5513668. DOI: 10.1007/978-1-4939-7015-5_9.


eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein models.

Brylinski M PLoS Comput Biol. 2014; 10(9):e1003829.

PMID: 25232727 PMC: 4168975. DOI: 10.1371/journal.pcbi.1003829.


Computational methods for analysis and inference of kinase/inhibitor relationships.

Ferre F, Palmeri A, Helmer-Citterich M Front Genet. 2014; 5:196.

PMID: 25071826 PMC: 4075008. DOI: 10.3389/fgene.2014.00196.


Are predicted protein structures of any value for binding site prediction and virtual ligand screening?.

Skolnick J, Zhou H, Gao M Curr Opin Struct Biol. 2013; 23(2):191-7.

PMID: 23415854 PMC: 3659186. DOI: 10.1016/j.sbi.2013.01.009.


References
1.
Okram B, Nagle A, Adrian F, Lee C, Ren P, Wang X . A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol. 2006; 13(7):779-86. DOI: 10.1016/j.chembiol.2006.05.015. View

2.
Brylinski M, Skolnick J . Q-Dock: Low-resolution flexible ligand docking with pocket-specific threading restraints. J Comput Chem. 2008; 29(10):1574-88. PMC: 2726574. DOI: 10.1002/jcc.20917. View

3.
Deuse T, Velotta J, Hoyt G, Govaert J, Taylor V, Masuda E . Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation. 2008; 85(6):885-92. DOI: 10.1097/TP.0b013e318166acc4. View

4.
DeWeese-Scott C, Moult J . Molecular modeling of protein function regions. Proteins. 2004; 55(4):942-61. DOI: 10.1002/prot.10519. View

5.
Scapin G, Patel S, Lisnock J, Becker J, LoGrasso P . The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol. 2003; 10(8):705-12. DOI: 10.1016/s1074-5521(03)00159-5. View